

Cosentyx Rheum - Mechanism of action - HCP

[Prescribing information](#)

Image



Image



Cosentyx® (secukinumab): Mechanism of action

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related

arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

[Cosentyx Summary of Product Characteristics \(SmPC\) can be found here](#)

Cosentyx blocks IL-17A, a key cytokine associated with inflammation in PsA, axSpA and JIA¹⁻¹¹

Image



Increased levels of IL-17A are found in the tissues of:

- PsA patients with psoriatic plaques¹
- blood of patients with **PsA and AS**^{7,14}

Image




IL-17A is a pro-inflammatory cytokine. Its overproduction may contribute to signs and **symptoms seen in patients with PsA, AS, and nr-axSpA**^{1,11,15}

Cosentyx blocks IL-17A, irrespective of its source^{1,12,13}

[Watch the video](#) below to discover how Cosentyx works.

Image



How does Cosentyx work?



This video has been produced and funded by Novartis Pharmaceuticals Ltd.
Intended for UK healthcare professionals only.
September 2023 | 286183

VIDEO

Image



Efficacy in PSA

Image



Efficacy in axSpA

Image



Efficacy in JIA

Image



Dosing

Image



Safety profile

Image



HCP resources

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.¹

Therapeutic Indications¹

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have

responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ERA; enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17A, interleukin 17A; IL-23, interleukin 23; JIA, juvenile idiopathic arthritis; MRI, magnetic resonance imaging; MTX, methotrexate; NK, natural killer; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics; TNF α , tumour necrosis factor alpha.

References

1. Cosentyx® (secukinumab) Summary of Product Characteristics.
2. Smith JA & Colbert RA. *Arthritis Rheumatol* 2014;66(2):231–241.
3. Cua DJ, et al. *Nat Rev Immunol* 2010;10(7):479–489.
4. Baeten D, et al. *N Engl J Med* 2015;373(26):2534–2548.
5. Mease PJ, et al. *N Engl J Med* 2015;373(14):1329–1339.
6. McInnes IB, et al. *Lancet* 2015;386(9999):1137–1146.
7. Mills KHG. *Nat Rev Immunol* 2023;23(1):38–54.
8. Raychaudhuri SP & Raychaudhuri SK. *Arthritis Res Ther* 2017;19(1):51.
9. Paroli M, et al. *Medicina* 2022;58:1552.
10. Lubberts E. *Nat Rev Rheumatol* 2015;11(7):415–429.
11. Deodhar A, et al. *Arthritis Rheumatol* 2021;73(1):110–120.
12. Schön M & Erpenbeck L. *Front Immunol* 2018;9:1323.

13. Gorelick J, et al. *Practical Dermatol* 2016;12:35–50.
14. Tsukazaki H & Kaito T. *Int J Mol Sci* 2020;21(17):6401.
15. Miossec P & Kolls JK. *Nat Rev Drug Discov* 2012;11(10):763–776.

UK | April 2025 | FA-11384553

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL: <https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/moa>